Study on high on-aspirin platelet reactivity in diabetic mice based on metabonomics

doi:10.12092/j.issn.1009-2501.2020.03.002

Abstract

Abstract: AIM: To explore the underlying mechanism of aspirin-related high on-aspirin platelet reactivity (HAPR) in diabetic state from the perspective of endogenous metabolic changes in metabolomics. METHODS:Type 2 diabetes mellitus (T2DM) mice model was established by the combination treatment of high-fat diet and streptozotocin injections. Mice were randomly divided into Normal group, T2DM group, Normal+aspirin group and T2DM+aspirin group. GC/TOF-MS was used to determine the plasmatic endogenous metabolites of mice. The data were analyzed applying multivariate statistical method. RESULTS:The expression of platelet CD62P and ratio of TXB2/6-keto-PGF1α in the plasma of female T2DM mice showed no significant difference compared with that of the model group. The degree of divergence between normal and normal+aspirin groups was significantly greater than that between T2DM and T2DM+aspirin groups. Biochemical metabolic pathway analysis revealed that HAPR in diabetic mice was linked to glycolysis, gluconeogenesis, pyruvate metabolism, citric acid cycle, ascorbic acid metabolism, and arachidonic acid metabolic pathways. CONCLUSION:The different metabolites obtained in metabolome assay suggests that the HAPR in diabetic state involved several different metabolic pathways, which can better elucidate the biological mechanism of diabetes-associated HAPR.

Key words: metabonomics, diabetes, high on-aspirin platelet reactivity

CLC Number:

R969
R587.1

ZHANG Haowen, ZHU Yejin, WU Xiang, CHEN Hanyu, SONG Yulei, BIAN Yaoyao, HAO Haiping, CHEN Xiaohu. Study on high on-aspirin platelet reactivity in diabetic mice based on metabonomics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 246-256.

References

［1］Wisman PP,Roest M,Asselbergs FW,et al.Platelet-reactivity tests identify patients at risk of secondary cardiovascular events:a systematic review and meta-analysis［J］.J Throm Haemost,2014,12(5):736-747.
［2］Trialists C, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials［J］. Lancet, 2009, 373(9678):1849-1860.
［3］Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies［J］. Lancet, 2010,375(9733):2215-2222.
［4］Huxley R，Barzi F，Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies［J］. BMJ, 2006,332(7533):73-78.
［5］Sarwar N，Gao P，Seshasai SR，et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies［J］. Lancet, 2010,375(9733):2215.
［6］Simpson SH, Abdelmoneim AS, Omran D, et al. Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin［J］. Am J Med, 2014,127(1):1-9.
［7］Holmes E，Wilson ID，Nicholson JK. Metabolic phenotyping in health and disease［J］. Cell,2008,134(5):714-717.
［8］Nicholson JK, Lindon JC. Systems biology: Metabonomics［J］. Nature, 2008,455(7216):1054-1056.
［9］Linden MD. Toward a guided approach to platelet activation in diabetes［J］. J Thromb Thrombolysis, 2013,35(2):175-177.
［10］Thomas A,Rahmanian S,Bordbar A,et al.Network reconstruction of platelet metabolism identifies metabolic signature for aspirin resistance［J］.Sci Rep-Uk,2014,4.
［11］Ertugrul DT, Tutal E, Yildiz M, et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus［J］. J Clin Endocr Metab, 2010,95(6):2897-2901.
［12］Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes［J］. Diabetes, 2006,55(6):1695-1704.
［13］Liu L, Aa J, Wang G, et al. Differences in metabolite profile between blood plasma and serum［J］. Anal Biochem, 2010,406(2):105-112.
［14］Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery［J］. Circulation, 2003,108(5):542-547.
［15］Michelson AD. Evaluation of platelet function by flow cytometry［J］. Methods, 2000,21(3):259-270.
［16］Sakata C, Kawasaki T, Kato Y, et al. ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without "aspirin dilemma"［J］. Thromb Res, 2013,132(1):56-62.
［17］Watala C, Ulicna O, Golanski J, et al. High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats: a multiparametric aggregation study［J］. Blood Coagul Fibrinolysis, 2006,17(2):113-124.
［18］Kobzar G，Mardla V，Samel N. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors［J］. Platelets, 2011,22(5):338-344.
［19］Takenaka T, Takahashi K, Kobayashi T, et al. Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patients［J］. Clin Nephrol, 2002,58(1):33.
［20］Chen LY，Mehta P，Mehta JL. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function［J］. Circulation, 1996,93(93):1740-1746.
［21］Liani R, Halvorsen B, Sestili S, et al. Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients［J］. Free Radic Biol Med, 2012,52(8):1318-1324.
［22］Ravi S, Johnson MS, Chacko BK, et al. Modification of platelet proteins by 4-hydroxynonenal: Potential Mechanisms for inhibition of aggregation and metabolism［J］. Free Radical Bio Med, 2016,91:143-153.
［23］Zhang H, Xie H, Zheng X, et al. Salicylic acid retention impairs aspirin reactivity in type 2 diabetes［J］. Eur J Pharmacol, 2017,794:234-245.
［24］Yildiz BS, Ozkan E, Esin F, et al. Does high serum uric acid level cause aspirin resistance［J］? Blood Coagul Fibrin, 2016,27(4):412-418.

[1]	DU Caifeng, MAO Yunan, GAO Jia, WANG Juan, LI Xiaoye, TIAN Junsheng, LIU Hongqi. Research on serum metabolic markers of menopausal syndrome based on 1H-NMR metabolomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 961-968.
[2]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[3]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[4]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[5]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[6]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[7]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[8]	DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo. Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
[9]	CAI Jing, PAN Binjing, LIU Jingfang. Research progress on the relationship between hypoglycemic drugs and sarcopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
[10]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[11]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[12]	ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin. Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
[13]	LI Hao, LI Ling, XIA Zhiping, YE Qifa, PENG Guizhu. FXR agonist GW4064 ameliorates tacrolimus-induced abnormalities in glucose metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 466-472.
[14]	SHAO Xi, YU Yanan, HUANG Yuhan, WANG Xiaotong, LING Hongwei, LV Dongmei, WANG Tao. Predictive factors associated with weight response to exenatide in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 287-294.
[15]	LV Xiaohan, LIN Rong. Association of Lin28 with tumor, cardiovascular disease and diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 205-211.